At some point, most adults notice it: a patch across the cheeks that looks a shade darker than the rest of the face, a mark that lingered long after a breakout healed, or small brown spots that seem to appear a little faster every summer. Uneven tone is one of the most common reasons people seek out a dermatologist, and it is also one of the more misunderstood, since the word "hyperpigmentation" gets used loosely to describe several genuinely different conditions with different causes and, importantly, different treatments.
Getting the specific cause right matters more here than in almost any other area of skincare, because a product or routine built for one type of pigment change can do very little for another, or in some cases make things worse. This guide walks through what actually drives acquired hyperpigmentation in adults, how to tell the common causes apart, and what the evidence genuinely supports for treating each one, with particular attention to how this plays out across Canada's genuinely diverse range of skin tones.
What Is Actually Happening: Hyperpigmentation vs Just Having a Certain Skin Tone
It helps to start with a distinction that gets blurred constantly in casual conversation. Your baseline skin color, the tone you were genetically given, reflects how much melanin your melanocytes naturally produce and is not a condition at all. Hyperpigmentation is something different: an acquired, localized, or more widespread increase in melanin above your own personal baseline, triggered by a specific driver like sun exposure, inflammation, hormones, or certain medications. The goal in treating hyperpigmentation is never to lighten skin below its natural tone. It is to bring a specific darkened area back toward the baseline it started at.
One more distinction matters enormously for how treatable any given patch of discoloration actually is: depth. Pigment sitting in the epidermis, the outermost skin layer, responds relatively well to topical treatment and fades over a matter of weeks to months. Pigment that has settled deeper into the dermis is considerably more stubborn and can persist for a year or longer regardless of what you apply, which is part of why some pigment issues respond quickly to treatment while others frustrate people for years.
How Melanin Production Actually Gets Triggered
Melanin is produced inside melanocytes through an enzyme-driven pathway, with a copper-containing enzyme called tyrosinase acting as the rate-limiting step, essentially the bottleneck controlling how much pigment gets made. Several different signals can push this process into overdrive, and understanding which one is doing the pushing in your specific case is the key to picking an effective approach.
Ultraviolet radiation is the most familiar trigger. UV exposure generates oxidative stress and prompts skin cells to release signaling molecules that directly stimulate melanocytes to ramp up pigment production.
Visible light is a genuinely underappreciated driver, especially in darker skin. This is one of the more clinically important and less widely known facts in this entire topic. Visible light, specifically the blue-violet portion of the spectrum, activates a light-sensitive receptor on melanocytes that triggers intense, prolonged pigmentation, and it does this preferentially in medium-to-darker skin tones. This matters practically because a sunscreen that only blocks UV light leaves this entire pathway unaddressed.
Inflammation is its own independent trigger, separate from sun exposure entirely. Inflammatory signals released during a breakout, an eczema flare, an injury, or even a cosmetic procedure directly stimulate the same pigment-producing machinery. This is the mechanism behind post-inflammatory hyperpigmentation, and it explains why a healed pimple can leave behind a mark that lasts far longer than the pimple itself ever did.
Hormones shift how responsive your melanocytes are in the first place. Estrogen and progesterone increase how strongly melanocytes respond to the triggers above, which is why pregnancy, oral contraceptives, and certain hormonal shifts are so consistently tied to specific pigmentation patterns.
Diagram illustrating the proposed mechanism by which post-inflammatory hyperpigmentation (PIH) occurs. In this illustration, the major (proposed) pathways involved in PIH include the release of inflammatory cytokines from keratinocytes and growth factors from dermal fibroblasts. Following the production of melanin, its deposition in the dermis can occur in two ways, which are illustrated in this diagram: (1) Melanin can be directly deposited into the dermis through the gaps in the basal lamina; (2) macrophages engulf melanin in the epidermis; these melanophages migrate from the epidermis to the dermis, which contributes to dermal pigmentation.
https://onlinelibrary.wiley.com/doi/10.1111/pcmr.13038
The Main Causes of Adult Hyperpigmentation, and How to Tell Them Apart
Melasma shows up as symmetric, often somewhat blurred brown-to-gray patches, typically across the cheeks, forehead, and upper lip. It disproportionately affects women, particularly those with medium-to-deeper skin tones, and is driven by a genuine combination of sun exposure, hormonal factors like pregnancy or oral contraceptive use, and a real genetic predisposition. Melasma is increasingly understood as involving the whole surrounding skin environment, not just the melanocytes themselves, which helps explain why it can be so persistent and prone to returning even after successful treatment.
Post-inflammatory hyperpigmentation, often shortened to PIH, follows any prior inflammation or injury, most commonly acne, but also eczema, a cut, a burn, or a cosmetic procedure, and it appears in the same distribution as whatever caused it. This disproportionately affects darker skin tones and is one of the more common complications people encounter after laser or peel treatments if those procedures were not carefully matched to their skin tone.
Solar lentigines, commonly called sun spots or age spots, are discrete, well-defined brown macules that build up from years of cumulative sun exposure, typically appearing on the face, hands, and other frequently exposed areas as a genuine marker of photoaging.
Ephelides, or freckles, are small sun-responsive spots that tend to appear early in life in people with lighter, more UV-reactive skin, darkening with summer sun exposure and fading somewhat over winter.
Drug-induced pigmentation is worth knowing about since it catches people off guard: certain antibiotics, antimalarial medications, some heart medications, and various chemotherapy drugs can all cause pigment changes as a side effect, through a few different mechanisms depending on the specific drug involved.
Hormonal and endocrine causes extend beyond melasma specifically. Pregnancy, oral contraceptives, and certain hormonal or endocrine conditions can all shift melanocyte activity in ways that produce visible pigment changes.
Why This Looks So Different Across Skin Tones
This is worth addressing directly, since Canada's population spans an unusually wide range of skin tones, and this genuinely changes both risk and treatment strategy. Deeper skin tones, generally Fitzpatrick phototypes IV through VI, carry a higher burden of both melasma and post-inflammatory hyperpigmentation, and these patterns tend to be more persistent once they appear, largely because deeper skin tones naturally have more melanin-producing capacity and higher baseline tyrosinase activity to begin with. Darker skin is relatively well protected against UV-driven sunburn, but it is considerably more susceptible to the visible-light-driven pigmentation described above, which is a genuinely important nuance, since it means "less sunburn risk" does not translate to "less pigmentation risk" for this group. Our guide to ingredients for dark spots and hyperpigmentation in Black skin goes deeper into this specific pattern and what the evidence supports.
Deeper phototypes also carry a higher risk when it comes to procedural treatment. Energy-based devices like lasers work partly by targeting melanin, which means more melanin in the surrounding skin increases the risk of the device causing new pigment problems rather than solving existing ones, a real consideration worth discussing carefully with a dermatologist experienced in treating a range of skin tones before pursuing any laser-based option.
What the Evidence Actually Supports, by Treatment Category
Photoprotection, including visible light, is the genuine foundation, not an optional add-on. This deserves to be stated as clearly as possible: inadequate photoprotection, and specifically a lack of visible-light coverage, is the single leading cause of treatment failure and relapse across this entire category of conditions. Standard sunscreens block UV effectively but often do little against visible light, which is exactly the wavelength driving so much pigmentation in darker skin tones, specifically. Tinted sunscreens containing iron oxides address this gap directly, and research comparing tinted to UV-only sunscreen has found better melasma control with the tinted version over an equivalent period. If pigmentation is a real concern for you, looking specifically for a tinted, broad-spectrum formula rather than a standard clear sunscreen is one of the more evidence-backed choices available. MiraGlow's Natural Finish BB Cream with Lightweight Coverage & SPF offers daily tinted coverage alongside sun protection, which is worth considering specifically for the visible-light angle on top of standard UV defense.
Hydroquinone-based triple combination cream remains the clinical gold standard, but it is a supervised prescription treatment, not a self-directed purchase. Combining hydroquinone with a retinoid and a mild corticosteroid produces the most consistently effective topical results available for melasma and PIH in the research. This needs to be said plainly, though: it is not meant for continuous, unsupervised long-term use, since prolonged hydroquinone exposure carries a real risk of a condition called ochronosis, a paradoxical darkening that can be difficult to reverse, and the corticosteroid component carries its own risks with extended use. This is a treatment to pursue with a dermatologist prescribing and monitoring it, cycling it appropriately, rather than something to source and self-administer indefinitely.
Azelaic acid is a well-tolerated, genuinely useful option, including during pregnancy. Azelaic acid has real supporting evidence for both melasma and PIH, tends to be gentler than hydroquinone, and is specifically considered a pregnancy-compatible option when hydroquinone and retinoids are not appropriate choices.
Topical tranexamic acid, often paired with niacinamide, has emerged as a genuinely competitive alternative to hydroquinone. Several trials have found this combination performs comparably to hydroquinone with fewer side effects and less rebound after stopping, making it a reasonable option for anyone wanting to avoid hydroquinone specifically or looking for something better suited to long-term maintenance.
Oral tranexamic acid is the best-supported systemic option for more stubborn cases, but it requires real medical screening first. Research using a low, twice-daily dose has shown substantial improvement in melasma severity scores compared to placebo, with lower doses performing just as well as higher ones. This is genuinely one of the more effective options available for melasma that has not responded adequately to topical treatment, but it carries a blood-clotting risk and needs to be prescribed only after screening for personal or family history of clotting disorders, use of hormonal contraception, and smoking status, which makes this firmly a conversation to have with a physician rather than something to pursue independently.
Cysteamine is a newer option worth knowing about, particularly for shorter-duration melasma. Research has found cysteamine performing comparably to hydroquinone-based triple combination therapy in some analyses, without carrying the same ochronosis risk, though it does come with a distinctive odor and some irritation potential that limits tolerability for certain people.
Retinoids help, but need to be introduced carefully given the irony involved. Retinoids show real benefit for both melasma and PIH, partly by speeding the turnover that clears pigment-containing cells from the surface. The catch is that retinoid-related irritation can itself trigger new post-inflammatory pigmentation, particularly in darker skin, which makes a slow, careful introduction genuinely important rather than optional. MiraGlow's Age Defying Face Serum with Retinol & Collagen can play a role here, and our retinol for beginners guide is worth reading first if pigmentation, rather than just fine lines, is your primary concern, since the introduction pace matters even more in that context.
Vitamin C and niacinamide are genuinely useful, modest, well-tolerated adjuncts rather than primary treatments. Both offer real antioxidant support and mild pigment-modulating effects, and niacinamide specifically has an added benefit against pollution-driven pigmentation, but neither is likely to meaningfully resolve established melasma or significant PIH on its own. MiraGlow's Brightening Face Serum with Niacinamide & Vitamin C fits well as exactly this kind of supportive, daily layer, particularly for maintenance once a more targeted treatment has done the heavier lifting. Our guide on combining niacinamide and vitamin C for dark spots covers how to use these two together effectively.
Procedures are adjuncts reserved for select, well-managed cases, never a first move. Chemical peels, lasers, and similar energy-based devices can help, particularly for solar lentigines specifically, but they carry meaningfully higher risk of causing new pigmentation problems in darker skin tones, and for melasma specifically, lasers are generally considered a last-resort option given real concerns about relapse and rebound darkening. Microneedling has a somewhat better safety profile across skin tones since it largely spares the epidermis, making it a more broadly reasonable adjunct when a procedure is genuinely warranted.
How Long Does Any of This Actually Take
Topical treatments generally show meaningful improvement over eight to sixteen weeks, with hydroquinone-based options often showing benefit within eight to twelve weeks and continued improvement with certain retinoids extending out to six months. Oral tranexamic acid typically shows real benefit by eight to twelve weeks, continuing to improve through sixteen. Epidermal PIH, the more superficial and treatable kind, tends to fade over weeks to a few months, while dermal PIH can persist for a year or longer regardless of treatment, which is genuinely worth knowing before assuming a stubborn mark means your treatment has failed rather than that you are simply dealing with deeper pigment.
Why Hyperpigmentation Treatment So Often Fails or Comes Back
This is worth walking through directly, since it explains a lot of frustrating experiences people have with pigmentation treatment. Inadequate sun protection, particularly missing visible-light coverage, is the single most common reason for relapse. Overly aggressive use of retinoids, acids, or peels can cause irritation that itself triggers new pigmentation, effectively working against the very goal you started with. Choosing an aggressive laser or device for melasma specifically, or using one without appropriately conservative settings in darker skin, can trigger rebound pigmentation that leaves things worse than before treatment started. Treating deep, dermal pigment with a topical designed only to address surface-level melanin will understandably underdeliver, since it is simply not reaching where the problem actually sits. And stopping treatment abruptly without any maintenance plan, or missing an ongoing hormonal or medication-related trigger that is still active, both commonly bring pigmentation right back after initial success.
What to Avoid
Do not rely on a standard, untinted sunscreen if melasma or PIH is a real concern for you, particularly if you have a deeper skin tone. Missing visible-light protection is the most consistently cited reason pigmentation treatment fails to hold.
Avoid sourcing hydroquinone independently for open-ended, unsupervised use, given the real ochronosis risk with prolonged exposure, and be cautious about introducing retinoids or exfoliating acids aggressively while actively treating pigmentation, since the irritation they cause can itself generate new dark marks in exactly the skin most prone to this in the first place. And think carefully before pursuing an aggressive laser or energy-based device for melasma specifically without a dermatologist experienced across a range of skin tones guiding the decision, since the wrong modality or settings can genuinely make pigmentation worse rather than better.
Expert Opinion
Hyperpigmentation in adults is rarely one single condition, and successful treatment depends entirely on correctly identifying which of several genuinely distinct processes, melasma, post-inflammatory pigmentation, solar lentigines, or a hormonal or drug-related cause, is actually driving what you are seeing, since the effective approach differs meaningfully across each. The evidence is clearest and most consistent for rigorous, visible-light-inclusive photoprotection as the non-negotiable foundation underneath any other treatment, for hydroquinone-based triple combination therapy as the most effective supervised topical option, and for oral tranexamic acid as the best-supported systemic choice for melasma resistant to topical treatment alone, provided appropriate screening rules out clotting risk first. Darker skin tones carry a disproportionate burden of both melasma and PIH and face a meaningfully higher procedural risk, which argues for a more conservative, topical-first approach and real caution before pursuing energy-based devices. My practical recommendation for any patient dealing with persistent uneven tone is to start with a proper diagnosis of which condition is actually present, commit to genuinely comprehensive daily photoprotection, including visible-light coverage as the foundation of everything else, and treat this as a chronic, relapse-prone condition requiring ongoing maintenance rather than a problem that gets solved once and never returns.
The Bottom Line
Uneven skin tone in adults almost always has an identifiable cause, whether that is melasma, post-inflammatory marks, sun-driven spots, or a hormonal or medication-related trigger, and correctly identifying which one you are dealing with changes everything about what will actually help. Photoprotection that specifically includes visible light is the foundation nothing else can substitute for; hydroquinone-based treatment remains the most effective supervised option available, and gentler adjuncts like azelaic acid, tranexamic acid combinations, and antioxidants offer real, if more modest, support alongside it.
This is a chronic, relapse-prone category of skin concerns for most people, not a problem with a single fix. Building a routine around consistent, comprehensive protection and realistic, maintained treatment will get you considerably further than chasing the next product promising to erase discoloration for good.
References
Global Consensus on Melanin Hyperpigmentation Disorders. Journal of the European Academy of Dermatology and Venereology. Delphi consensus statement. 2026.
Pigmentary Disorders Society. International Delphi Consensus on Melasma Management. Journal of the European Academy of Dermatology and Venereology. 2026.
Sarkar, R., et al. Systematic review of 174 controlled trials on topical and systemic melasma treatments. 2023.
Nautiyal, A., et al. Review of hyperpigmentation causes, mechanisms, and diagnostic approach. 2021.
Maghfour, J., et al. Focused review on the pathophysiology of post-inflammatory hyperpigmentation. Pigment Cell & Melanoma Research. 2022.
Amici, J., et al. Review of procedural treatment risk and phototype-based safety considerations in hyperpigmentation. 2023.
Zhou, L., et al. Review of visible light-driven pigmentation and tinted sunscreen efficacy in melasma. 2023.
Miao, F., et al. Review of hormonal, aging, and recurrence factors in adult hyperpigmentation. 2025.
Austin, E., et al. Review of hydroquinone and topical melasma treatment evidence. 2019.
Persson, L., et al. Review of comparative treatment timelines for hyperpigmentation therapies. 2026.
Liu, W., et al. Review of UV and visible light mechanisms in melanogenesis and pigmentary disorders. 2023.
Lyons, A., et al. Review of visible light protection and tinted sunscreen clinical outcomes. 2020.
Grimes, P., et al. Review of pigmentary disorder management across skin phototypes. 2025.
Lee, S., et al. Review of laser and energy-based device risk in darker skin phototypes. 2026.
Soares, J., et al. Review of post-inflammatory hyperpigmentation risk following procedural treatment. 2024.
Nautiyal, Avni, and Sarika Wairkar. "Management of hyperpigmentation: Current treatments and emerging therapies." Pigment Cell & Melanoma Research 34 (2021): 1000 - 1014. https://doi.org/10.1111/pcmr.12986.
Maghfour, J., J. Olayinka, I. Hamzavi, and T. Mohammad. "A Focused review on the pathophysiology of post‐inflammatory hyperpigmentation." Pigment Cell & Melanoma Research 35 (2022): 320 - 327. https://doi.org/10.1111/pcmr.13038.
Amici, J., O. Cogrel, M. Jourdan, C. Raimbault, Ludivine Canchy, D. Kerob, Diane C Madfes, Yan Tian, and E. Araviiskaia. "Expert recommendations on supportive skin care for non‐surgical and surgical procedures." Journal of the European Academy of Dermatology and Venereology 37 (2023): 16 - 33. https://doi.org/10.1111/jdv.18855.
Lyons, A., C. Trullàs, I. Kohli, I. Hamzavi, and H. Lim. "Photoprotection Beyond Ultraviolet Radiation: A Review of Tinted Sunscreens.." Journal of the American Academy of Dermatology (2020). https://doi.org/10.1016/j.jaad.2020.04.079.
Liu, Wei, Qin Chen, and Yumin Xia. "New Mechanistic Insights of Melasma." Clinical, Cosmetic and Investigational Dermatology 16 (2023): 429 - 442. https://doi.org/10.2147/ccid.s396272.
